Monthly Archives: June 2015

26 June 2015

Parkwalk closes Orthox investment

By |June 26th, 2015|

We are pleased to announce that Parkwalk VI, the Opportunities EIS Fund and the University of Oxford Isis Fund II have made an investment in Orthox,  a tissue regenerative orthopaedic implant company with technology spun out of Oxford University.

Orthox is a medical device company founded in 2008 to exploit FibroFix, a novel silk-based biomaterial platform, for the […]

Perpetuum – Parkwalk closes follow on investment

By |June 17th, 2015|

We have recently closed a follow-on investment in Perpetuum for the Parkwalk UK Tech Fund VI and the Opportunities EIS Fund, alongside existing investors IP Group and ETF.

Perpetuum engineered, produced and commercialised the world’s first practical electromagnetic vibration harvesting micro-generator delivering the power required to transmit large amounts of autonomous wireless sensor data reliably from remotely monitored assets.

Perpetuum’s technology […]

Parkwalk closes Reduse investment

By |June 3rd, 2015|

We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in Reduse, a spin out from the Low Carbon Materials Processing Group at the University of Cambridge.

Reduse are seeking to change the way laser printed office paper is treated post use. Instead of disposal, recycling and shredding a […]

Revolymer – signs global licence with Solvay for SPC formulations

By |June 3rd, 2015|

Revolymer signs global licence to its encapsulation technology with Solvay in the field of Sodium Percarbonate (SPC) for liquid product formulations

Revolymer, the polymer technology company, is pleased to announce that it has signed a further licence in its Consumer Specialties business area with the international chemicals group Solvay. Under the terms of the deal, […]

Omega Diagnostics – Development Update

By |June 1st, 2015|

Omega Diagnostics Group PLC – Development Update – Visitect® CD4 and Allergy

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following development update on its infectious disease and allergy projects.

Infectious Disease – Visitect® CD4 update
Since the trading update on 15 April 2015, the Company has continued to […]

Parkwalk closes Bounts investment

By |June 1st, 2015|

We are pleased to announce that the University of Oxford Isis Fund I has closed its final investment into Bounts, an Isis software incubator spin-out company.

Bounts is a digital health platform and app that has partnered with multiple leading retailers to motivate and reward individuals for taking more exercise. Bounts gets users rewards and […]